Systematic review: Fatigue in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 2, 2010, Pages 131-143

  Van Langenberg, D R ^a   Gibson, P R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE ACTIVITY; DISEASE SEVERITY; ENTERITIS; FATIGUE; HUMAN; MEDLINE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REMISSION; REVIEW; SYSTEMATIC REVIEW;

CHRONIC DISEASE; FATIGUE; HUMANS; INFLAMMATORY BOWEL DISEASES; PREVALENCE;

EID: 77953780510     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04347.x     Document Type: Review

References (141)

1. Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Eur J Cancer Care 1996 5 : 8 23.
2. Minderhoud IM, Oldenburg B, van Dam PS, van Berge Henegouwen GP. High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency. Am J Gastroenterol 2003 98 : 1088 1093.
3. de Rooy EC, Toner BB, Maunder RG, et al. Concerns of patients with inflammatory bowel disease: results from a clinical population. Am J Gastroenterol 2001 96 : 1816 1821.
4. Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appelbaum MI. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci 1989 34 : 1379 1386.
5. Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol 2001 13 : 567 572.
6. Lai JS, Cella D, Chang CH, et al. Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale. Qual Life Res 2003 12 : 485 501.
7. Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res 2004 56 : 157 170.
8. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 1998 12 : 369 377.
9. Craig A, Tran Y, Wijesuriya N, Boord P. A controlled investigation into the psychological determinants of fatigue. Biol Psychol 2006 72 : 78 87.
10. van der Linden G, Chalder T, Hickie I, Koschera A, Sham P, Wessely S. Fatigue and psychiatric disorder: different or the same? Psychol Med 1999 29 : 863 868.
11. Breitbart W, Alici Y. Pharmacologic treatment options for cancer-related fatigue: current state of clinical research. Clin J Oncol Nurs 2008 12 : 27 36.
12. Echteld MA, Passchier J, Teunissen S, Claessen S, de Wit R, van der Rijt CC. Multidimensional fatigue and its correlates in hospitalised advanced cancer patients. Eur J Cancer 2007 43 : 1030 1036.
13. Hjollund NH, Andersen JH, Bech P, Hjollund NH, Andersen JH, Bech P. Assessment of fatigue in chronic disease: a bibliographic study of fatigue measurement scales. Health & Quality of Life Outcomes 2007 5 : 12.
14. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989 46 : 1121 1123.
15. Kleinman L, Zodet MW, Hakim Z, et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000 9 : 499 508.
16. Merkies IS, Schmitz PI, Samijn JP, van der Meche FG, van Doorn PA. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 1999 53 : 1648 1654.
17. Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 2007 66 : 936 939.
18. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997 13 : 63 74.
19. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005 32 : 811 819.
20. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002 94 : 528 538.
21. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995 39 : 315 325.
22. Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage 2004 27 : 14 23.
23. Lou JS, Kearns G, Oken B, Sexton G, Nutt J. Exacerbated physical fatigue and mental fatigue in Parkinson's disease. Mov Disord 2001 16 : 190 196.
24. Unal G, de Boer JB, Borsboom GJ, Brouwer JT, Essink-Bot M, de Man RA. A psychometric comparison of health-related quality of life measures in chronic liver disease. J Clin Epidemiol 2001 54 : 587 596.
25. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994 18 (Suppl 1 S79 83.
26. Newton JL, Jones DE, Henderson E, et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008 57 : 807 813.
27. Simren M, Svedlund J, Posserud I, Bjornsson ES, Abrahamsson H. Predictors of subjective fatigue in chronic gastrointestinal disease. Aliment Pharmacol Ther 2008 28 : 638 647.
28. Mota DD, Pimenta CA. Self-report instruments for fatigue assessment: a systematic review. Res Theory Nurs Pract 2006 20 : 49 78.
29. Kos D, Kerckhofs E, Nagels G, et al. Assessing fatigue in multiple sclerosis: Dutch modified fatigue impact scale. Acta Neurol Belg 2003 103 : 185 191.
30. Fisk JD, Doble SE. Construction and validation of a fatigue impact scale for daily administration (D-FIS). Qual Life Res 2002 11 : 263 272.
31. Marcus SB, Strople JA, Neighbors K, et al. Fatigue and health-related quality of life in pediatric inflammatory bowel disease. Clin Gastroenterol Hepatol 2009 7 : 554 561.
32. Minderhoud IM, Samsom M, Oldenburg B. Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol 2007 13 : 2089 2093.
33. Bjornsson E, Simren M, Olsson R, Chapman RW. Fatigue in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2004 39 : 961 968. (Pubitemid 39388460)
34. Szigethy E, Levy-Warren A, Whitton S, et al. Depressive symptoms and inflammatory bowel disease in children and adolescents: a cross-sectional study. J Pediatr Gastroenterol Nutr 2004 39 : 395 403.
35. Joyce JC, Waljee AK, Khan T, et al. Identification of symptom domains in ulcerative colitis that occur frequently during flares and are responsive to changes in disease activity. Health & Quality of Life Outcomes 2008 6 : 69.
36. Graff LA, Walker JR, Lix L, et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 2006 4 : 1491 1501.
37. Tench CM, McCurdie I, White PD, D'Cruz DP. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology 2000 39 : 1249 1254.
38. Jones SD, Koh WH, Steiner A, Garrett SL, Calin A. Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors. J Rheumatol 1996 23 : 487 490.
39. Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ. Fatigue in primary biliary cirrhosis. Gut 1998 43 : 705 710.
40. Hassoun Z, Willems B, Deslauriers J, Nguyen BN, Huet PM. Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci 2002 47 : 2674 2681.
41. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996 23 : 1407 1417.
42. Giovannoni G, Thompson AJ, Miller DH, Thompson EJ. Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology 2001 57 : 676 681. (Pubitemid 32782997)
43. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2008 14 : 234 254.
44. Yount S, Sorensen MV, Cella D, Sengupta N, Grober J, Chartash EK. Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clin Exp Rheumatol 2007 25 : 838 846.
45. Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008 103 : 3132 3141.
46. Bjornsson E, Simren M, Olsson R, Chapman RW. Fatigue is not a specific symptom in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2005 17 : 351 357.
47. Ranganath VK, Khanna D, Paulus HE. ACR remission criteria and response criteria. Clin Exp Rheumatol 2006 24 : S14 21.
48. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979 77 : 843 846.
49. Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum 2007 57 : 935 942.
50. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002 122 : 512 530.
51. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007 132 : 763 786.
52. Swiergiel AH, Smagin GN, Johnson LJ, Dunn AJ. The role of cytokines in the behavioral responses to endotoxin and influenza virus infection in mice: effects of acute and chronic administration of the interleukin-1-receptor antagonist (IL-1ra). Brain Res 1997 776 : 96 104.
53. Kelley KW, Bluthe RM, Dantzer R, et al. Cytokine-induced sickness behavior. Brain Behav Immun 2003 17 (Suppl 1 S112 8.
54. Bower JE, Ganz PA, Lin Tao M, et al. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res 2009 15 : 5534 5540.
55. Bower JE. Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun 2007 21 : 863 871.
56. Swain MG. Fatigue in chronic disease. Clin Sci (Lond) 2000 99 : 1 8.
57. Bearn J, Wessely S. Neurobiological aspects of the chronic fatigue syndrome. Eur J Clin Invest 1994 24 : 79 90. (Pubitemid 24222969)
58. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999 79 : 1 71.
59. Simon GE, Von Korff M. Medical co-morbidity and validity of DSM-IV depression criteria. Psychol Med 2006 36 : 27 36.
60. Williamson RJ, Purcell S, Sterne A, et al. The relationship of fatigue to mental and physical health in a community sample. Soc Psychiatry Psychiatr Epidemiol 2005 40 : 126 132.
61. Brown LF, Kroenke K. Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 2009 50 : 440 447.
62. Andrews H, Barczak P, Allan RN. Psychiatric illness in patients with inflammatory bowel disease. Gut 1987 28 : 1600 1604.
63. Andrews JM, Mountifield RE, Van Langenberg DR, Bampton PA, Holtmann GJ. Un-promoted issues in inflammatory bowel disease (IBD): opportunities to optimise care. Intern Med J 2010 40 : 173 182.
64. Leue C, van Os J, Neeleman J, de Graaf R, Vollebergh W, Stockbrugger RW. Bidirectional associations between depression/anxiety and bowel disease in a population based cohort. J Epidemiol Community Health 2005 59 : 434.
65. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 2005 54 : 1481 1491.
66. Ng V, Millard W, Lebrun C, Howard J. Low-intensity exercise improves quality of life in patients with Crohn's disease. Clin J Sport Med 2007 17 : 384 388.
67. Rietjens GJ, Kuipers H, Adam JJ, et al. Physiological, biochemical and psychological markers of strenuous training-induced fatigue. Int J Sports Med 2005 26 : 16 26.
68. Szigethy E, Craig AE, Iobst EA, et al. Profile of depression in adolescents with inflammatory bowel disease: implications for treatment. Inflamm Bowel Dis 2009 15 : 69 74.
69. Ghia JE, Blennerhassett P, Deng Y, Verdu EF, Khan WI, Collins SM. Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology 2009 136 : 2280 2288. e1-4.
70. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 2008 29 : 287 291.
71. Anisman H, Merali Z, Poulter MO, Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des 2005 11 : 963 972.
72. Maes M, Mihaylova I, Ruyter MD, Kubera M, Bosmans E. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett 2007 28 : 826 831.
73. Young SN, Leyton M. The role of serotonin in human mood and social interaction. Insight from altered tryptophan levels. Pharmacol Biochem Behav 2002 71 : 857 865.
74. Kubera M, Basta-Kaim A, Budziszewska B, et al. Effect of amantadine and imipramine on immunological parameters of rats subjected to a forced swimming test. Int J Neuropsychopharmacol 2006 9 : 297 305.
75. Kubera M, Symbirtsev A, Basta-Kaim A, et al. Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol J Pharmacol 1996 48 : 503 506.
76. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999 461 : 25 46.
77. Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP. Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch Neurol 2001 58 : 1081 1086.
78. Rogers NL, Szuba MP, Staab JP, Evans DL, Dinges DF. Neuroimmunologic aspects of sleep and sleep loss. Semin Clin Neuropsychiatry 2001 6 : 295 307.
79. Hong S, Mills PJ, Loredo JS, Adler KA, Dimsdale JE. The association between interleukin-6, sleep, and demographic characteristics. Brain Behav Immun 2005 19 : 165 172.
80. Irwin M. Effects of sleep and sleep loss on immunity and cytokines. Brain Behav Immun 2002 16 : 503 512.
81. Irwin MR, Wang M, Ribeiro D, et al. Sleep loss activates cellular inflammatory signaling. Biol Psychiatry 2008 64 : 538 540.
82. Shearer WT, Reuben JM, Mullington JM, et al. Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J Allergy Clin Immunol 2001 107 : 165 170.
83. Meier-Ewert HK, Ridker PM, Rifai N, et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol 2004 43 : 678 683.
84. Spath-Schwalbe E, Lange T, Perras B, Fehm HL, Born J. Interferon-alpha acutely impairs sleep in healthy humans. Cytokine 2000 12 : 518 521.
85. Spath-Schwalbe E, Hansen K, Schmidt F, et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998 83 : 1573 1579.
86. Takahashi S, Kapas L, Fang J, Krueger JM. Somnogenic relationships between tumor necrosis factor and interleukin-1. Am J Physiol 1999 276 : R1132 40.
87. Dinges DF, Douglas SD, Zaugg L, et al. Leukocytosis and natural killer cell function parallel neurobehavioral fatigue induced by 64 hours of sleep deprivation. J Clin Invest 1994 93 : 1930 1939.
88. Benca RM, Quintas J. Sleep and host defenses: a review. Sleep 1997 20 : 1027 1037.
89. Cremonini F, Camilleri M, Zinsmeister AR, Herrick LM, Beebe T, Talley NJ. Sleep disturbances are linked to both upper and lower gastrointestinal symptoms in the general population. Neurogastroenterol Motil 2009 21 : 128 135.
90. Fass R, Fullerton S, Tung S, Mayer EA. Sleep disturbances in clinic patients with functional bowel disorders. Am J Gastroenterol 2000 95 : 1195 2000.
91. Ranjbaran Z, Keefer L, Stepanski E, Farhadi A, Keshavarzian A. The relevance of sleep abnormalities to chronic inflammatory conditions. Inflamm Res 2007 56 : 51 7.
92. Ranjbaran Z, Keefer L, Farhadi A, Stepanski E, Sedghi S, Keshavarzian A. Impact of sleep disturbances in inflammatory bowel disease. J Gastroenterol Hepatol 2007 22 : 1748 1753.
93. Tang Y, Preuss F, Turek FW, Jakate S, Keshavarzian A. Sleep deprivation worsens inflammation and delays recovery in a mouse model of colitis. Sleep Med 2009 10 : 597 603.
94. Keefer L, Stepanski EJ, Ranjbaran Z, Benson LM, Keshavarzian A. An initial report of sleep disturbance in inactive inflammatory bowel disease. J Clin Sleep Med 2006 2 : 409 416.
95. Gandevia SC, Butler JE, Taylor JL. Viewpoint: fatigue mechanisms determining exercise performance: integrative physiology is systems physiology. J Appl Physiol 2008 104 : 1546.
96. Bautmans I, Gorus E, Njemini R, Mets T. Handgrip performance in relation to self-perceived fatigue, physical functioning and circulating IL-6 in elderly persons without inflammation. BMC Geriatr 2007 7 : 5.
97. Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr 1998 67 : 919 926.
98. Capristo E, Addolorato G, Mingrone G, Greco AV, Gasbarrini G. Effect of disease localization on the anthropometric and metabolic features of Crohn's disease. Am J Gastroenterol 1998 93 : 2411 2419.
99. Schneeweiss B, Lochs H, Zauner C, et al. Energy and substrate metabolism in patients with active Crohn's disease. J Nutr 1999 129 : 844 848.
100. Schneider SM, Al-Jaouni R, Filippi J, et al. Sarcopenia is prevalent in patients with Crohn's disease in clinical remission. Inflamm Bowel Dis 2008 14 : 1562 1568.
101. Valentini L, Schaper L, Buning C, et al. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission. Nutrition 2008 24 : 694 702.
102. Cuoco L, Vescovo G, Castaman R, et al. Skeletal muscle wastage in Crohn's disease: a pathway shared with heart failure? Int J Cardiol 2008 127 : 219 227.
103. Russell DM, Leiter LA, Whitwell J, Marliss EB, Jeejeebhoy KN. Skeletal muscle function during hypocaloric diets and fasting: a comparison with standard nutritional assessment parameters. Am J Clin Nutr 1983 37 : 133 138.
104. Sousa Guerreiro C, Cravo M, Costa AR, et al. A comprehensive approach to evaluate nutritional status in Crohn's patients in the era of biologic therapy: a case-control study. Am J Gastroenterol 2007 102 : 2551 2556.
105. Filippi J, Al-Jaouni R, Wiroth JB, Hebuterne X, Schneider SM. Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm Bowel Dis 2006 12 : 185 191.
106. Ayre KJ, Hulbert AJ. Effects of changes in dietary fatty acids on isolated skeletal muscle functions in rats. J Appl Physiol 1996 80 : 464 471.
107. Grau JM, Casademont J, Pedrol E, et al. Chronic fatigue syndrome: studies on skeletal muscle. Clin Neuropathol 1992 11 : 329 332.
108. Ward KA, Das G, Berry JL, et al. Vitamin D status and muscle function in post-menarchal adolescent girls. J Clin Endocrinol Metab 2009 94 : 559 563.
109. Galland L. Magnesium and inflammatory bowel disease. Magnesium 1988 7 : 78 83.
110. Matteini AM, Walston JD, Fallin MD, et al. Markers of B-vitamin deficiency and frailty in older women. J Nutr Health Aging 2008 12 : 303 308.
111. Sjogren A, Floren CH, Nilsson A. Evaluation of magnesium status in Crohn's disease as assessed by intracellular analysis and intravenous magnesium infusion. Scand J Gastroenterol 1988 23 : 555 561.
112. Bloxam DL, Tan JC, Parkinson CE. Non-protein bound zinc concentration in human plasma and amniotic fluid measured by ultrafiltration. Clin Chim Acta 1984 144 : 81 93.
113. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004 53 : 1190 1197.
114. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007 13 : 1545 1553.
115. Street ME, de'Angelis G, Camacho-Hubner C, et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Horm Res 2004 61 : 159 164.
116. De Pascalis B, Bianchi A, Satta MA, et al. Growth hormone in inflammatory bowel disease. Eur Rev Med Pharmacol Sci 2006 10 : 13 6.
117. Robinson RJ, Iqbal SJ, Al-Azzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. Aliment Pharmacol Ther 1998 12 : 21 5.
118. Lee TWTI, Iser JH, Sparrow MJ, Newnham ED, Headon BJ, Gibson PR. Thiopurines, a previously unrecognised cause for fatigue in patients with inflammatory bowel disease. J Crohn Colitis 2009 3 : 196 199.
119. Carter MJ, Lobo AJ, Travis SP, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004 5 : V1 16.
120. Elkjaer MM, Reinisch G, Durovicova W, et al. IBD patients need in health quality of care: ECCO consensus. J Crohn Colitis 2008 2 : 181 188.
121. Lakatos PL. Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it? World J Gastroenterol 2009 15 : 4234 4239.
122. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006 23 : 577 585.
123. Langmead L, Chitnis M, Rampton DS. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis 2002 8 : 174 179.
124. D'Inca R, Garribba AT, Vettorato MG, et al. Use of alternative and complementary therapies by inflammatory bowel disease patients in an Italian tertiary referral centre. Dig Liver Dis 2007 39 : 524 529.
125. Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 1999 37 : 126 139.
126. Kalaitzakis E, Carlsson E, Josefsson A, Bosaeus I. Quality of life in short-bowel syndrome: impact of fatigue and gastrointestinal symptoms. Scand J Gastroenterol 2008 43 : 1057 1065.
127. Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002 8 : 237 243.
128. Hagell P, Hoglund A, Reimer J, et al. Measuring fatigue in Parkinson's disease: a psychometric study of two brief generic fatigue questionnaires. J Pain Symptom Manage 2006 32 : 420 432.
129. Vasconcelos OM Jr., Prokhorenko OA, Kelley KF, et al. A comparison of fatigue scales in postpoliomyelitis syndrome. Arch Phys Med Rehabil 2006 87 : 1213 1217.
130. Putzki N, Katsarava Z, Vago S, Diener HC, Limmroth V. Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients. Eur Neurol 2008 59 : 136 142.
131. Theander K, Cliffordson C, Torstensson O, Jakobsson P, Unosson M. Fatigue Impact Scale: Its validation in patients with chronic obstructive pulmonary disease. Psychol Health Med 2007 12 : 470 484.
132. Segal B, Thomas W, Rogers T, et al. Prevalence, severity, and predictors of fatigue in subjects with primary Sjogren's syndrome. Arthritis Rheum 2008 59 : 1780 1787.
133. Kim SH, Son BH, Hwang SY, et al. Fatigue and depression in disease-free breast cancer survivors: prevalence, correlates, and association with quality of life. J Pain Symptom Manage 2008 35 : 644 655.
134. Skowera A, Peakman M, Cleare A, Davies E, Deale A, Wessely S. High prevalence of serum markers of coeliac disease in patients with chronic fatigue syndrome. J Clin Pathol 2001 54 : 335 336.
135. Ledochowski M, Widner B, Bair H, Probst T, Fuchs D. Fructose- and sorbitol-reduced diet improves mood and gastrointestinal disturbances in fructose malabsorbers. Scand J Gastroenterol 2000 35 : 1048 1052.
136. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. J Gastroenterol Hepatol 2010 25 : 252 258.
137. Mercadante S, Ferrera P, Villari P, David F, Giarratano A, Riina S. Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med 2009 12 : 60 3.
138. Mikocka-Walus AA, Turnbull DA, Andrews JM, Moulding NT, Holtmann GJ. The effect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008 28 : 475 483.
139. Mitsuyama K, Matsumoto S, Masuda J, et al. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease. Anticancer Res 2007 27 : 3749 3756.
140. Doucet M, Russell AP, Leger B, et al. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007 176 : 261 269.
141. Cooper MR, Bird HM, Steinberg M. Efficacy and safety of modafinil in the treatment of cancer-related fatigue. Ann Pharmacother 2009 43 : 721 725.